Last reviewed 2026-05-26 · How we verify

IMPROSULFAN

Phase 2 active Small molecule ✓ Verified May 2026

IMPROSULFAN is a improsulfan drug. It is currently in Phase 2 development.

Improsulfan is thought to work by inhibiting a specific enzyme or pathway, but the exact mechanism is not well understood.

Improsulfan is a small molecule. It is also known by the synonyms IMPROSULFANO and IMPROSULFAN.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IMPROSULFAN
Drug class	improsulfan
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a factory, and improsulfan is a tool that helps regulate the factory's production line. By inhibiting a specific enzyme or pathway, improsulfan may help slow down or speed up certain cellular processes, but the precise details of how it does this are still unclear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IMPROSULFAN CI brief — competitive landscape report
IMPROSULFAN updates RSS · CI watch RSS

Frequently asked questions about IMPROSULFAN

What is IMPROSULFAN?

IMPROSULFAN is a improsulfan drug.

How does IMPROSULFAN work?

Improsulfan is thought to work by inhibiting a specific enzyme or pathway, but the exact mechanism is not well understood.

What drug class is IMPROSULFAN in?

IMPROSULFAN belongs to the improsulfan class. See all improsulfan drugs at /class/improsulfan.

What development phase is IMPROSULFAN in?

IMPROSULFAN is in Phase 2.

Drug class: All improsulfan drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing